Contents

Highlights of This Issue 3297

HIGHLIGHTS

Special Report

3299 AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

3319 ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?

Adam M. Lee and Robert B. Diasio

See article p. 3378

3322 New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK

Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

3329 Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Christine A. Pratilas and David B. Solit

3335 The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment

Ivor Caro and Jennifer A. Low

3339 Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

3340 BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood

Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Bielawski, and Burkhard Brandt

3349 Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

3356 Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletić, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønning

3366 A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

CANCER THERAPY: PRECLINICAL

3378 Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston

See commentary p. 3319

3386 The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo


3390 Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy

Darya Alizadeh, Leying Zhang, Christine E. Brown, Omar Farkuh, Michael C. Jensen, and Behnam Badie
Role of Type-1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans
Mitsugu Fujita, Michael E. Scheuerer, Stacy A. Decker, Heather A. McDonald, Gary Kohanbash, Edward R. Kastenhuber, Hisashi Kato, Melissa L. Bondy, John R. Ohlfest, and Hideho Okada

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang, Xiao-Dong Zhu, Hui-Chuan Sun, Yu-Quan Xiong, Peng-Yuan Zhuang, Hua-Xiang Xu, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, and Zhao-You Tang

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR
Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky

Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression
Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Gu-Cheng Hsu, Huan-Ming Hsu, Jar Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.J. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaire, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Bissas, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marighoula Varla-Leftherioti, Eric von Hofe, and Constantin N. Baxevanis

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into LoxP-conditional p53 or pten;Ink4a/Arf;K-Ras^R12;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.